JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
SAN DIEGO - Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a market capitalization of $27.35 million and showing strong momentum with a 7.67% return over the past week, has announced a strategic partnership with Rosy Wellness, a digital women’s health platform, to promote the upcoming DARE to PLAY Sildenafil Cream, a topical treatment for female sexual arousal disorder. According to InvestingPro data, analysts have set price targets between $12 and $14, suggesting significant potential upside for this niche player in the biopharmaceutical industry. The collaboration, revealed today, aims to increase awareness among consumers and healthcare providers about the new product expected to be available by prescription in the United States in the fourth quarter of 2025.
The DARE to PLAY Sildenafil Cream is a proprietary topical formulation containing sildenafil citrate, the same active ingredient found in Viagra®, but tailored to enhance blood flow to genital tissues in women as part of the sexual arousal response. Rosy Wellness, with its community of over 250,000 women and recommendation by more than 8,000 healthcare professionals, will leverage its digital reach and content-driven model to support the launch. While the company maintains a conservative financial position with more cash than debt on its balance sheet, InvestingPro analysis indicates current challenges with revenue generation, highlighting the strategic importance of this partnership.
The partnership will focus on educational outreach and digital support to destigmatize conversations around female sexual health. This includes the development of educational campaigns and a companion care platform to provide comprehensive support for users of the DARE to PLAY Sildenafil Cream.
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, expressed confidence in the collaboration’s ability to make a meaningful advancement in addressing the significantly underserved area of female sexual health. Lyndsey Harper, MD, Founder and CEO of Rosy, echoed this sentiment, emphasizing the joint effort to enhance sexual wellness education and support for women.
Daré Bioscience’s mission includes bringing to market innovative evidence-based solutions for unmet needs in women’s health. Their portfolio features various product candidates, including XACIATO™ (clindamycin phosphate) vaginal gel for bacterial vaginosis and other products in clinical development for contraception, pelvic pain, fertility, and menopause.
The announcement of this collaboration is based on a press release statement and indicates a shared commitment between Daré Bioscience and Rosy Wellness to advance sexual health equity and ensure women have access to necessary information and solutions. With an overall Financial Health score of "FAIR" according to InvestingPro, which offers comprehensive analysis through its Pro Research Report covering over 1,400 US stocks, the company’s strategic initiatives will be crucial for its future market position.
In other recent news, Dare Bioscience reported its financial results for the first quarter of 2025, revealing a comprehensive loss of $4.4 million. The company is focusing on cost reduction and product innovation, with plans to launch four new products, including Sildenafil Cream and vaginal probiotics. Despite the loss, Dare Bioscience aims to start generating revenue by the fourth quarter of 2025. The company reduced its general and administrative expenses by 14% and research and development expenses by 31% compared to the same period last year. Dare Bioscience faces a working capital deficit of $9.4 million but maintains $10.3 million in cash and cash equivalents. The company is also advancing its Sildenafil Cream and hormone therapy through a dual-path strategy, pursuing FDA approval while commercializing via 503B compounding. Analysts from H.C. Wainwright have been actively engaging with Dare Bioscience, indicating continued interest in the company’s innovative approach. Additionally, Dare Bioscience is preparing for the DARE HPV Phase II clinical study and aims to submit the Sildenafil Cream Phase III study by the second quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.